Pharmaceutical US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase I/II portion of the Phase I/II/III FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). 23 June 2025